NASDAQ · Financial Statements

Regeneron Pharmaceuticals, Inc. (REGN) Financial Statements

$805.02 NASDAQ: REGN Market Cap $82.88B

Regeneron Pharmaceuticals, Inc. most recently reported annual revenue of $14.3B, net profit of $4.5B. Revenue grew at an average annual rate of 11.0% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Regeneron Pharmaceuticals, Inc.: Revenue rose from $4.9B in 2016 to $14.3B in 2025, a change of +195.1% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 27.4% to 24.9%, a shift of -2.4 percentage points; the most recent year shows net profit of $4.5B.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$4.9B$5.9B$6.7B$6.6B$8.5B$16.1B$12.2B$13.1B$14.2B$14.3B
Operating Expenses$3.5B$3.8B$4.2B$4.3B$4.9B$7.1B$6.8B$8.8B$10.2B$10.8B
Operating Profit$1.3B$2.1B$2.5B$2.2B$3.6B$8.9B$5.4B$4.3B$4.0B$3.6B
Operating Margin27.4%35.4%37.8%33.7%42.1%55.7%44.2%33.1%28.1%24.9%
Other Income$-1.0M$-1.0M$19.0M$219.0M$234.0M$379.0M$-527.0M$-149.0M$789.0M$1.7B
Interest$7.0M$25.0M$28.0M$30.0M$57.0M$57.0M$59.0M$73.0M$55.0M$44.0M
Depreciation$105.0M$145.0M$148.0M$210.0M$236.0M$286.0M$341.0M$421.0M$483.0M$544.0M
Profit Before Tax$1.3B$2.1B$2.6B$2.4B$3.8B$9.3B$4.9B$4.2B$4.8B$5.2B
Tax$32.7M$42.3M$4.3M$12.9M$7.8M$13.4M$10.7M$5.8M$7.7M$13.9M
Net Profit$896.0M$1.2B$2.4B$2.1B$3.5B$8.1B$4.3B$4.0B$4.4B$4.5B
EPS$7.70$10.34$21.29$18.46$30.52$71.97$38.22$34.77$38.34$41.48
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$3.4B$3.4B$3.1B$3.5B$3.7B$3.8B$3.0B$3.7B$3.8B$3.9B$3.6B$4.3B
Operating Expenses$2.2B$2.4B$2.4B$2.5B$2.5B$2.8B$2.4B$2.6B$2.7B$3.0B$3.0B$2.9B
Operating Profit$1.2B$1.1B$751.0M$1.1B$1.2B$990.0M$592.0M$1.1B$1.0B$880.0M$643.0M$1.4B
Operating Margin36.0%30.6%23.9%30.1%31.7%26.1%19.5%29.4%27.4%22.6%17.8%33.1%
Interest$18.0M$18.0M$16.0M$15.0M$14.0M$11.0M$9.0M$4.0M$19.0M$12.0M$13.0M$11.0M
Profit Before Tax$1.1B$1.1B$701.0M$1.6B$1.5B$958.0M$905.0M$1.5B$1.8B$1.0B$831.0M$1.5B
Tax$9.3M$-1.1M$-3.0M$12.0M$10.2M$4.2M$10.6M$8.4M$17.2M$19.1M$12.5M$15.1M
Net Profit$1.0B$1.2B$722.0M$1.4B$1.3B$918.0M$809.0M$1.4B$1.5B$845.0M$727.0M$1.3B
EPS$8.89$10.19$6.27$12.41$11.54$8.06$7.27$12.81$13.62$7.86$6.75$12.20

Over the 10 years reported for Regeneron Pharmaceuticals, Inc., borrowings increased from $481.0M in 2016 to $2.7B in 2025, cash stood at $3.1B in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.13 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$7.0B$8.8B$11.7B$14.8B$17.2B$25.4B$29.2B$33.1B$37.8B$40.6B
Current Assets$3.9B$5.6B$8.0B$7.7B$9.8B$14.0B$15.9B$19.5B$18.7B$18.0B
Cash$535.0M$813.0M$1.5B$1.6B$2.2B$2.9B$3.1B$2.7B$2.5B$3.1B
Inventory$399.0M$726.0M$1.2B$1.4B$1.9B$2.0B$2.4B$2.6B$3.1B$3.2B
Receivables$1.6B$2.0B$2.2B$2.8B$4.1B$6.0B$5.3B$5.7B$6.2B$5.7B
Fixed Assets$2.1B$2.4B$2.6B$2.9B$3.2B$3.5B$3.8B$4.1B$4.6B$5.1B
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$1.4B$2.1B$3.1B$4.9B$4.5B$9.6B$11.2B$13.5B$15.4B$15.7B
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$2.5B$2.6B$3.0B$3.7B$6.1B$6.7B$6.6B$7.1B$8.4B$9.3B
Current Liabilities$1.2B$1.1B$1.4B$2.1B$2.7B$3.9B$3.1B$3.4B$3.9B$4.4B
Borrowings$481.0M$703.0M$709.0M$714.0M$2.7B$2.7B$2.7B$2.7B$2.7B$2.7B
Other Liabilities$2.0B$1.9B$2.3B$3.0B$3.4B$4.0B$3.8B$4.4B$5.7B$6.6B
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$4.4B$6.1B$8.8B$11.1B$11.0B$18.8B$22.7B$26.0B$29.4B$31.3B

For Regeneron Pharmaceuticals, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $4.1B; free cash flow was positive in 10 of 10 years; financing activities used $4.0B in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$1.5B$1.3B$2.2B$2.4B$2.6B$7.1B$5.0B$4.6B$4.4B$5.0B
Investing Cash Flow$-1.6B$-1.3B$-1.8B$-2.5B$-685.0M$-5.9B$-4.4B$-4.1B$-3.2B$-1.5B
Financing Cash Flow$-660.0M$-302.0M$-379.0M$-652.0M$-4.0B$-3.7B$-3.0B$-2.9B$-3.7B$-4.0B
Net Cash Flow$-274.0M$278.0M$655.0M$150.0M$577.0M$691.0M$221.0M$-382.0M$-249.0M$635.0M
Free Cash Flow$974.0M$1.0B$1.8B$2.0B$2.0B$6.5B$4.4B$3.7B$3.7B$4.1B

Valuation & Return Ratios

MetricValue
PEG Ratio60.43
EV / EBITDA14.04
FCF Yield4.34%
Quick Ratio2.78
Interest Coverage71.66
Return 1Y40.55%
Return 3Y1.04%
Return 5Y43.16%

Regeneron Pharmaceuticals, Inc. (REGN) financials — frequently asked questions

What is Regeneron Pharmaceuticals, Inc.'s annual revenue?

Regeneron Pharmaceuticals, Inc. (REGN) reported annual revenue of $14.3B in its most recent fiscal year.

What is Regeneron Pharmaceuticals, Inc.'s net profit?

Regeneron Pharmaceuticals, Inc. (REGN) reported net profit of $4.5B in its most recent fiscal year.

What is REGN EV/EBITDA?

Regeneron Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 14.04.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
REGN Overview REGN Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.